{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:44:08Z","timestamp":1792464248837,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"the Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["Project grants #376770"],"award-info":[{"award-number":["Project grants #376770"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"the Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["Project grants #376770"],"award-info":[{"award-number":["Project grants #376770"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"the Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["Project grants #376770"],"award-info":[{"award-number":["Project grants #376770"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"the Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["Project grants #376770"],"award-info":[{"award-number":["Project grants #376770"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Sepsis is a prevalent life-threatening condition related to a systemic infection, and with unresolved issues including refractory septic shock and organ failures. Endogenously released catecholamines are often inefficient to maintain blood pressure, and low reactivity to exogenous catecholamines with risk of sympathetic overstimulation is well documented in septic shock. In this context, apelinergics are efficient and safe inotrope and vasoregulator in rodents. However, their utility in a larger animal model as well as the limitations with regards to the enzymatic breakdown during sepsis, need to be investigated. The therapeutic potential and degradation of apelinergics in sepsis were tested experimentally and in a cohort of patients. (1) 36 sheep with or without fecal peritonitis-induced septic shock (a large animal experimental design aimed to mimic the human septic shock paradigm) were evaluated for hemodynamic and renal responsiveness to incremental doses of two dominant apelinergics: apelin-13 (APLN-13) or Elabela (ELA), and (2) 52 subjects (33 patients with sepsis\/septic shock and 19 healthy volunteers) were investigated for early levels of endogenous apelinergics in the blood, the related enzymatic degradation profile, and data regarding sepsis outcome. APLN-13 was the only one apelinergic which efficiently improved hemodynamics in both healthy and septic sheep. Endogenous apelinergic levels early rose, and specific enzymatic breakdown activities potentially threatened endogenous apelin system reactivity and negatively impacted the outcome in human sepsis. Short-term exogenous APLN-13 infusion is helpful in stabilizing cardiorenal functions in ovine septic shock; however, this ability might be impaired by specific enzymatic systems triggered during the early time course of human sepsis. Strategies to improve resistance of APLN-13 to degradation and\/or to overcome sepsis-induced enzymatic breakdown environment should guide future works.<\/jats:p>","DOI":"10.1038\/s41598-021-02087-4","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T11:02:20Z","timestamp":1637665340000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Apelin-13 in septic shock: effective in supporting hemodynamics in sheep but compromised by enzymatic breakdown in patients"],"prefix":"10.1038","volume":"11","author":[{"given":"David","family":"Coquerel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lamoureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Chagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kien","family":"Tr\u00e2n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Fortin-Pellerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e9nie","family":"Delile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Sainsily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Fournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey-Ann","family":"Dumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mannix","family":"Auger-Messier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Sarret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Marsault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Praud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e0s","family":"F\u00fcl\u00f6p","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lesur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"key":"2087_CR1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMc1312359","volume":"369","author":"DC Angus","year":"2013","unstructured":"Angus, D. C. & van der Poll, T. Severe sepsis and septic shock. N. Engl. J. Med. 369, 2063. https:\/\/doi.org\/10.1056\/NEJMc1312359 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2087_CR2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1097\/CCM.0000000000003023","volume":"46","author":"A Schuler","year":"2018","unstructured":"Schuler, A. et al. The impact of acute organ dysfunction on long-term survival in sepsis. Crit. Care Med. 46, 843\u2013849. https:\/\/doi.org\/10.1097\/CCM.0000000000003023 (2018).","journal-title":"Crit. Care Med."},{"key":"2087_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13613-018-0449-8","volume":"8","author":"O Lesur","year":"2018","unstructured":"Lesur, O., Delile, E., Asfar, P. & Radermacher, P. Hemodynamic support in the early phase of septic shock: A review of challenges and unanswered questions. Ann. Intensive Care 8, 102. https:\/\/doi.org\/10.1186\/s13613-018-0449-8 (2018).","journal-title":"Ann. Intensive Care"},{"key":"2087_CR4","doi-asserted-by":"publisher","first-page":"9753","DOI":"10.1073\/pnas.97.17.9753","volume":"97","author":"H Macarthur","year":"2000","unstructured":"Macarthur, H., Westfall, T. C., Riley, D. P., Misko, T. P. & Salvemini, D. Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. Proc. Natl. Acad. Sci. U.S.A. 97, 9753\u20139758. https:\/\/doi.org\/10.1073\/pnas.97.17.9753 (2000).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2087_CR5","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1007\/s00134-016-4249-z","volume":"42","author":"DT Andreis","year":"2016","unstructured":"Andreis, D. T. & Singer, M. Catecholamines for inflammatory shock: a Jekyll-and-Hyde conundrum. Intensive Care Med. 42, 1387\u20131397. https:\/\/doi.org\/10.1007\/s00134-016-4249-z (2016).","journal-title":"Intensive Care Med."},{"key":"2087_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/SHK.0000000000000879","volume":"48","author":"C Hartmann","year":"2017","unstructured":"Hartmann, C., Radermacher, P., Wepler, M. & Nussbaum, B. Non-hemodynamic effects of catecholamines. Shock 48, 390\u2013400. https:\/\/doi.org\/10.1097\/SHK.0000000000000879 (2017).","journal-title":"Shock"},{"key":"2087_CR7","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1164\/ajrccm.160.2.9810073","volume":"160","author":"D Annane","year":"1999","unstructured":"Annane, D. et al. Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach. Am. J. Respir. Crit. Care Med. 160, 458\u2013465. https:\/\/doi.org\/10.1164\/ajrccm.160.2.9810073 (1999).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2087_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13054-018-1942-z","volume":"22","author":"D Coquerel","year":"2018","unstructured":"Coquerel, D. et al. The apelinergic system as an alternative to catecholamines in low-output septic shock. Crit. Care 22, 10. https:\/\/doi.org\/10.1186\/s13054-018-1942-z (2018).","journal-title":"Crit. Care"},{"key":"2087_CR9","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1161\/HYPERTENSIONAHA.109.134619","volume":"54","author":"JJ Maguire","year":"2009","unstructured":"Maguire, J. J., Kleinz, M. J., Pitkin, S. L. & Davenport, A. P. [Pyr1]apelin-13 identified as the predominant apelin isoform in the human heart: vasoactive mechanisms and inotropic action in disease. Hypertension 54, 598\u2013604. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.134619 (2009).","journal-title":"Hypertension"},{"key":"2087_CR10","doi-asserted-by":"publisher","first-page":"2962","DOI":"10.1021\/acs.jmedchem.5b01549","volume":"59","author":"A Murza","year":"2016","unstructured":"Murza, A. et al. Discovery and structure-activity relationship of a bioactive fragment of ELABELA that modulates vascular and cardiac functions. J. Med. Chem. 59, 2962\u20132972. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01549 (2016).","journal-title":"J. Med. Chem."},{"key":"2087_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvx061","author":"T Sato","year":"2017","unstructured":"Sato, T. et al. ELABELA\u2014APJ axis protects from pressure overload heart failure and Angiotensin II-induced cardiac damage. Cardiovasc. Res. https:\/\/doi.org\/10.1093\/cvr\/cvx061 (2017).","journal-title":"Cardiovasc. Res."},{"key":"2087_CR12","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00688.2020","author":"D Coquerel","year":"2021","unstructured":"Coquerel, D. et al. Galphai-biased apelin analogue protects against isoproterenol-induced myocardial dysfunction in rats. Am. J. Physiol. https:\/\/doi.org\/10.1152\/ajpheart.00688.2020 (2021).","journal-title":"Am. J. Physiol."},{"key":"2087_CR13","doi-asserted-by":"publisher","first-page":"e1139","DOI":"10.1097\/CCM.0000000000002639","volume":"45","author":"D Coquerel","year":"2017","unstructured":"Coquerel, D. et al. ELABELA improves cardio-renal outcome in fatal experimental septic shock. Crit. Care Med. 45, e1139\u2013e1148. https:\/\/doi.org\/10.1097\/CCM.0000000000002639 (2017).","journal-title":"Crit. Care Med."},{"key":"2087_CR14","doi-asserted-by":"publisher","first-page":"e391","DOI":"10.1097\/CCM.0000000000002097","volume":"45","author":"F Chagnon","year":"2017","unstructured":"Chagnon, F. et al. Apelin compared with dobutamine exerts cardioprotection and extends survival in a rat model of endotoxin-induced myocardial dysfunction. Crit. Care Med. 45, e391\u2013e398. https:\/\/doi.org\/10.1097\/CCM.0000000000002097 (2017).","journal-title":"Crit. Care Med."},{"key":"2087_CR15","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1161\/01.CIR.0000091235.94914.75","volume":"108","author":"MM Chen","year":"2003","unstructured":"Chen, M. M. et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108, 1432\u20131439. https:\/\/doi.org\/10.1161\/01.CIR.0000091235.94914.75 (2003).","journal-title":"Circulation"},{"key":"2087_CR16","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/cc9102","volume":"14","author":"O Lesur","year":"2010","unstructured":"Lesur, O. et al. Proven infection-related sepsis induces a differential stress response early after ICU admission. Crit. Care 14, R131. https:\/\/doi.org\/10.1186\/cc9102 (2010).","journal-title":"Crit. Care"},{"key":"2087_CR17","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1124\/pr.119.017533","volume":"71","author":"C Read","year":"2019","unstructured":"Read, C. et al. International union of basic and clinical pharmacology. CVII. Structure and pharmacology of the apelin receptor with a recommendation that elabela\/toddler is a second endogenous peptide ligand. Pharmacol. Rev. 71, 467\u2013502. https:\/\/doi.org\/10.1124\/pr.119.017533 (2019).","journal-title":"Pharmacol. Rev."},{"key":"2087_CR18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3389\/fnins.2017.00092","volume":"11","author":"P Yang","year":"2017","unstructured":"Yang, P. et al. [Pyr1]Apelin-13(1\u201312) is a biologically active ACE2 metabolite of the endogenous cardiovascular peptide [Pyr1]Apelin-13. Front. Neurosci. 11, 92. https:\/\/doi.org\/10.3389\/fnins.2017.00092 (2017).","journal-title":"Front. Neurosci."},{"key":"2087_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1161\/HYPERTENSIONAHA.115.06892","volume":"68","author":"W Wang","year":"2016","unstructured":"Wang, W. et al. Angiotensin-converting enzyme 2 metabolizes and partially inactivates pyr-apelin-13 and apelin-17: physiological effects in the cardiovascular system. Hypertension 68, 365\u2013377. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.115.06892 (2016).","journal-title":"Hypertension"},{"key":"2087_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ejmech.2019.01.040","volume":"166","author":"C Fischer","year":"2019","unstructured":"Fischer, C. et al. Plasma kallikrein cleaves and inactivates apelin-17: Palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents. Eur. J. Med. Chem. 166, 119\u2013124. https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.040 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"2087_CR21","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/cbic.201600244","volume":"17","author":"SM McKinnie","year":"2016","unstructured":"McKinnie, S. M. et al. The metalloprotease neprilysin degrades and inactivates apelin peptides. ChemBioChem 17, 1495\u20131498. https:\/\/doi.org\/10.1002\/cbic.201600244 (2016).","journal-title":"ChemBioChem"},{"key":"2087_CR22","doi-asserted-by":"publisher","first-page":"6408","DOI":"10.1021\/acs.jmedchem.7b00723","volume":"60","author":"SMK McKinnie","year":"2017","unstructured":"McKinnie, S. M. K. et al. Synthetic modification within the \u201cRPRL\u201d region of apelin peptides: Impact on cardiovascular activity and stability to neprilysin and plasma degradation. J. Med. Chem. 60, 6408\u20136427. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00723 (2017).","journal-title":"J. Med. Chem."},{"key":"2087_CR23","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/SHK.0000000000001524","volume":"54","author":"C de Roquetaillade","year":"2020","unstructured":"de Roquetaillade, C. et al. Hemodynamic impact of cardiovascular antihypertensive medications in patients with sepsis-related acute circulatory failure. Shock 54, 315\u2013320. https:\/\/doi.org\/10.1097\/SHK.0000000000001524 (2020).","journal-title":"Shock"},{"key":"2087_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/SHK.0000000000001382","volume":"53","author":"MS Hsieh","year":"2020","unstructured":"Hsieh, M. S., How, C. K., Hsieh, V. C. & Chen, P. C. Preadmission antihypertensive drug use and sepsis outcome: impact of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Shock 53, 407\u2013415. https:\/\/doi.org\/10.1097\/SHK.0000000000001382 (2020).","journal-title":"Shock"},{"key":"2087_CR25","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1677\/joe.1.06804","volume":"189","author":"CJ Charles","year":"2006","unstructured":"Charles, C. J., Rademaker, M. T. & Richards, A. M. Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep. J. Endocrinol. 189, 701\u2013710. https:\/\/doi.org\/10.1677\/joe.1.06804 (2006).","journal-title":"J. Endocrinol."},{"key":"2087_CR26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00395-015-0521-6","volume":"111","author":"A Perjes","year":"2016","unstructured":"Perjes, A. et al. Characterization of apela, a novel endogenous ligand of apelin receptor, in the adult heart. Basic Res. Cardiol. 111, 2. https:\/\/doi.org\/10.1007\/s00395-015-0521-6 (2016).","journal-title":"Basic Res. Cardiol."},{"key":"2087_CR27","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1164\/rccm.201801-0064OC","volume":"198","author":"L Byrne","year":"2018","unstructured":"Byrne, L. et al. Unintended consequences: Fluid resuscitation worsens shock in an ovine model of endotoxemia. Am. J. Respir. Crit. Care Med. 198, 1043\u20131054. https:\/\/doi.org\/10.1164\/rccm.201801-0064OC (2018).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2087_CR28","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1097\/CCM.0b013e3181ef4694","volume":"38","author":"S Rehberg","year":"2010","unstructured":"Rehberg, S. et al. Effects of combined arginine vasopressin and levosimendan on organ function in ovine septic shock. Crit. Care Med. 38, 2016\u20132023. https:\/\/doi.org\/10.1097\/CCM.0b013e3181ef4694 (2010).","journal-title":"Crit. Care Med."},{"key":"2087_CR29","doi-asserted-by":"publisher","first-page":"18261","DOI":"10.1074\/jbc.M115.648238","volume":"290","author":"C Deng","year":"2015","unstructured":"Deng, C., Chen, H., Yang, N., Feng, Y. & Hsueh, A. J. Apela regulates fluid homeostasis by binding to the APJ receptor to activate Gi signaling. J. Biol. Chem. 290, 18261\u201318268. https:\/\/doi.org\/10.1074\/jbc.M115.648238 (2015).","journal-title":"J. Biol. Chem."},{"key":"2087_CR30","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1080\/10715762.2017.1313414","volume":"51","author":"P Zhang","year":"2017","unstructured":"Zhang, P. et al. Apelin-13 attenuates cisplatin-induced cardiotoxicity through inhibition of ROS-mediated DNA damage and regulation of MAPKs and AKT pathways. Free Radical Res. 51, 449\u2013459. https:\/\/doi.org\/10.1080\/10715762.2017.1313414 (2017).","journal-title":"Free Radical Res."},{"key":"2087_CR31","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1681\/ASN.2007070816","volume":"19","author":"M Azizi","year":"2008","unstructured":"Azizi, M. et al. Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J. Am. Soc. Nephrol. 19, 1015\u20131024. https:\/\/doi.org\/10.1681\/ASN.2007070816 (2008).","journal-title":"J. Am. Soc. Nephrol."},{"key":"2087_CR32","doi-asserted-by":"publisher","first-page":"687","DOI":"10.33594\/000000165","volume":"53","author":"C Boulkeroua","year":"2019","unstructured":"Boulkeroua, C. et al. Apelin-13 regulates vasopressin-induced aquaporin-2 expression and trafficking in kidney collecting duct cells. Cell. Physiol. Biochem. 53, 687\u2013700. https:\/\/doi.org\/10.33594\/000000165 (2019).","journal-title":"Cell. Physiol. Biochem."},{"key":"2087_CR33","doi-asserted-by":"publisher","first-page":"R120","DOI":"10.1186\/cc7972","volume":"13","author":"I Abboud","year":"2009","unstructured":"Abboud, I. et al. Pharmacokinetics of epinephrine in patients with septic shock: modelization and interaction with endogenous neurohormonal status. Crit. Care 13, R120. https:\/\/doi.org\/10.1186\/cc7972 (2009).","journal-title":"Crit. Care"},{"key":"2087_CR34","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1046\/j.1365-2125.1998.00833.x","volume":"46","author":"D Annane","year":"1998","unstructured":"Annane, D. et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br. J. Clin. Pharmacol. 46, 589\u2013597. https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00833.x (1998).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"2087_CR35","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/00003246-199209000-00011","volume":"20","author":"H Ensinger","year":"1992","unstructured":"Ensinger, H., Stein, B., Jager, O., Grunert, A. & Ahnefeld, F. W. Relationship between infusion rates, plasma concentrations, and cardiovascular and metabolic effects during the infusion of norepinephrine in healthy volunteers. Crit. Care Med. 20, 1250\u20131256. https:\/\/doi.org\/10.1097\/00003246-199209000-00011 (1992).","journal-title":"Crit. Care Med."},{"key":"2087_CR36","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3892\/etm.2014.1566","volume":"7","author":"W Zhang","year":"2014","unstructured":"Zhang, W. et al. Severe sepsis: Low expression of the renin-angiotensin system is associated with poor prognosis. Exp. Ther. Med. 7, 1342\u20131348. https:\/\/doi.org\/10.3892\/etm.2014.1566 (2014).","journal-title":"Exp. Ther. Med."},{"key":"2087_CR37","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1179\/096805104225003807","volume":"10","author":"Z Shariat-Madar","year":"2004","unstructured":"Shariat-Madar, Z. & Schmaier, A. H. The plasma kallikrein\/kinin and renin angiotensin systems in blood pressure regulation in sepsis. J. Endotoxin Res. 10, 3\u201313. https:\/\/doi.org\/10.1179\/096805104225003807 (2004).","journal-title":"J. Endotoxin Res."},{"key":"2087_CR38","doi-asserted-by":"publisher","first-page":"e1226","DOI":"10.1097\/CCM.0000000000002729","volume":"45","author":"BL Erwin","year":"2017","unstructured":"Erwin, B. L. et al. Evaluation of vasopressin for septic shock in patients on chronic renin-angiotensin-aldosterone system inhibitors. Crit. Care Med. 45, e1226\u2013e1232. https:\/\/doi.org\/10.1097\/CCM.0000000000002729 (2017).","journal-title":"Crit. Care Med."},{"key":"2087_CR39","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1161\/HYPERTENSIONAHA.119.13197","volume":"75","author":"WT Hsu","year":"2020","unstructured":"Hsu, W. T. et al. Effect of renin-angiotensin-aldosterone system inhibitors on short-term mortality after sepsis: A population-based cohort study. Hypertension 75, 483\u2013491. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13197 (2020).","journal-title":"Hypertension"},{"key":"2087_CR40","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1161\/01.cir.102.16.2011","volume":"102","author":"SE Orfanos","year":"2000","unstructured":"Orfanos, S. E. et al. Pulmonary capillary endothelium-bound angiotensin-converting enzyme activity in acute lung injury. Circulation 102, 2011\u20132018. https:\/\/doi.org\/10.1161\/01.cir.102.16.2011 (2000).","journal-title":"Circulation"},{"key":"2087_CR41","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1186\/s13054-018-2202-y","volume":"22","author":"LS Chawla","year":"2018","unstructured":"Chawla, L. S., Chen, S., Bellomo, R. & Tidmarsh, G. F. Angiotensin converting enzyme defects in shock: Implications for future therapy. Crit. Care 22, 274. https:\/\/doi.org\/10.1186\/s13054-018-2202-y (2018).","journal-title":"Crit. Care"},{"key":"2087_CR42","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1002\/rth2.12217","volume":"3","author":"V Raghunathan","year":"2019","unstructured":"Raghunathan, V. et al. The contact pathway and sepsis. Res. Pract. Thromb. Haemostas. 3, 331\u2013339. https:\/\/doi.org\/10.1002\/rth2.12217 (2019).","journal-title":"Res. Pract. Thromb. Haemostas."},{"key":"2087_CR43","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1021\/acs.jmedchem.7b01353","volume":"61","author":"K Tran","year":"2018","unstructured":"Tran, K. et al. A systematic exploration of macrocyclization in apelin-13: Impact on binding, signaling, stability, and cardiovascular effects. J. Med. Chem. 61, 2266\u20132277. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b01353 (2018).","journal-title":"J. Med. Chem."},{"key":"2087_CR44","doi-asserted-by":"publisher","first-page":"H747","DOI":"10.1152\/ajpheart.00365.2019","volume":"318","author":"JD Tune","year":"2020","unstructured":"Tune, J. D. et al. Distinct hemodynamic responses to (pyr)apelin-13 in large animal models. American journal of physiology. Heart Circ. Physiol. 318, H747\u2013H755. https:\/\/doi.org\/10.1152\/ajpheart.00365.2019 (2020).","journal-title":"Heart Circ. Physiol."},{"issue":"199","key":"2087_CR45","first-page":"208","volume":"39","author":"K Bayne","year":"1996","unstructured":"Bayne, K. Revised guide for the care and use of laboratory animals available. Am. Physiol. Soc. Physiologist 39(199), 208\u2013111 (1996).","journal-title":"Am. Physiol. Soc. Physiologist"},{"key":"2087_CR46","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.3892\/etm.2019.7961","volume":"18","author":"NE Stevens","year":"2019","unstructured":"Stevens, N. E. et al. High mobility group box protein 1 neutralization therapy in ovine bacteremia: Lessons learned from an ovine septic shock model incorporating intensive care support. Exp. Ther. Med. 18, 3271\u20133280. https:\/\/doi.org\/10.3892\/etm.2019.7961 (2019).","journal-title":"Exp. Ther. Med."},{"key":"2087_CR47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0140-6736(18)30696-2","volume":"392","author":"M Cecconi","year":"2018","unstructured":"Cecconi, M., Evans, L., Levy, M. & Rhodes, A. Sepsis and septic shock. Lancet 392, 75\u201387. https:\/\/doi.org\/10.1016\/S0140-6736(18)30696-2 (2018).","journal-title":"Lancet"},{"key":"2087_CR48","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1097\/CCM.0000000000003507","volume":"47","author":"YR Lankadeva","year":"2019","unstructured":"Lankadeva, Y. R. et al. Effects of fluid bolus therapy on renal perfusion, oxygenation, and function in early experimental septic kidney injury. Crit. Care Med. 47, e36\u2013e43. https:\/\/doi.org\/10.1097\/CCM.0000000000003507 (2019).","journal-title":"Crit. Care Med."},{"key":"2087_CR49","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/0006-291x(78)91322-0","volume":"80","author":"PJ Fraker","year":"1978","unstructured":"Fraker, P. J. & Speck, J. C. Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem. Biophys. Res. Commun. 80, 849\u2013857. https:\/\/doi.org\/10.1016\/0006-291x(78)91322-0 (1978).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2087_CR50","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1021\/jm501916k","volume":"58","author":"A Murza","year":"2015","unstructured":"Murza, A. et al. C-Terminal modifications of apelin-13 significantly change ligand binding, receptor signaling, and hypotensive action. J. Med. Chem. 58, 2431\u20132440. https:\/\/doi.org\/10.1021\/jm501916k (2015).","journal-title":"J. Med. Chem."},{"key":"2087_CR51","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer, M. et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315, 801\u2013810. https:\/\/doi.org\/10.1001\/jama.2016.0287 (2016).","journal-title":"JAMA"},{"key":"2087_CR52","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1007\/s00134-006-0378-0","volume":"32","author":"F Lauzier","year":"2006","unstructured":"Lauzier, F., Levy, B., Lamarre, P. & Lesur, O. Vasopressin or norepinephrine in early hyperdynamic septic shock: A randomized clinical trial. Intensive Care Med. 32, 1782\u20131789. https:\/\/doi.org\/10.1007\/s00134-006-0378-0 (2006).","journal-title":"Intensive Care Med."},{"key":"2087_CR53","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1093\/clinchem\/38.9.1785","volume":"38","author":"T Yandle","year":"1992","unstructured":"Yandle, T. et al. Assay of endopeptidase-2411 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clin. Chem. 38, 1785\u20131791 (1992).","journal-title":"Clin. Chem."},{"key":"2087_CR54","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1093\/ndt\/gfv025","volume":"30","author":"L Anguiano","year":"2015","unstructured":"Anguiano, L. et al. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease. Nephrol. Dial. Transplant. 30, 1176\u20131185. https:\/\/doi.org\/10.1093\/ndt\/gfv025 (2015).","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02087-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02087-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02087-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T17:16:03Z","timestamp":1670087763000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-02087-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["2087"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-02087-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]},"assertion":[{"value":"30 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22770"}}